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Background: Valvulogenesis and septation in the developing heart depend on the formation and remodeling of
endocardial cushions in the atrioventricular canal (AVC) and outflow tract (OFT). These cushions are invaded by a
subpopulation of endocardial cells that undergo an epithelial-mesenchymal transition in response to paracrine and
autocrine transforming growth factor β (TGFβ) signals. We previously demonstrated that the RNA binding protein
muscleblind-like 1 (MBNL1) is expressed specifically in the cushion endocardium, and knockdown of MBNL1 in
stage 14 embryonic chicken AVC explants enhances TGFβ-dependent endocardial cell invasion.
Results: In this study, we demonstrate that the effect of MBNL1 knockdown on invasion remains dependent on
TGFβ3 after it is no longer required to induce basal levels of invasion. TGFβ3, but not TGFβ2, levels are elevated in
medium conditioned by MBNL1-depleted AVC explants. TGFβ3 is elevated even when the myocardium is removed,
indicating that MBNL1 modulates autocrine TGFβ3 production in the endocardium. More TGFβ3-positive cells are
observed in the endocardial monolayer following MBNL1 knockdown. Addition of exogenous TGFβ3 to AVC
explants recapitulates the effects of MBNL1 knockdown. Time course experiments demonstrate that knockdown of
MBNL1 induces precocious TGFβ3 secretion, and early exposure to excess TGFβ3 induces precocious invasion.
MBNL1 expression precedes TGFβ3 in the AVC endocardium, consistent with a role in preventing precocious
autocrine TGFβ3 signaling. The stimulatory effects of MBNL1 knockdown on invasion are lost in stage 16 AVC
explants. Knockdown of MBNL1 in OFT explants similarly enhances cell invasion, but not activation. TGFβ is
necessary and sufficient to mediate this effect.
Conclusions: Taken together, these data support a model in which MBNL1 negatively regulates cell invasion in the
endocardial cushions by restricting the magnitude and timing of endocardial-derived TGFβ3 production.
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Cell invasionBackground
Epithelial-mesenchymal transition (EMT) is a critical
process in the formation of the valves and septa of the
heart. Prior to the onset of EMT, endocardial cushions
form in the atrioventricular canal (AVC) and outflow
tract (OFT) regions when localized deposition of extra-
cellular matrix separates the endocardial lining from the
myocardial wall of the heart tube. In response to induct-
ive signals from the adjacent myocardium, a subset of* Correspondence: ladda@ccf.org
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reproduction in any medium, provided the orendocardial cells within the AVC and OFT cushions
undergoes EMT and invades the cushion matrix [1-4].
Fusion and remodeling of the cellularized cushions in the
AVC gives rise to the mitral and tricuspid valves, and in
the OFT to the aortic and pulmonary valves. Dysregula-
tion of EMT or subsequent remodeling of the cushion
mesenchyme can cause valve and septal malformations
[5], which can range from mild to life threatening.
Endocardial cell EMT can be separated into two
distinct events: activation, in which cell polarity and cell-
cell contacts are lost, and invasion, in which the trans-
formed mesenchymal cells migrate into the matrix. In
the chick, both steps are induced by members of theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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required for activation, while TGFβ3 is required for inva-
sion [6,7]. TGFβ2 and TGFβ3 are both expressed in the
underlying myocardium prior to mesenchyme formation
[6,8,9]. In contrast, TGFβ3 is expressed in the cushion
endocardium only during stages of active mesenchyme
formation [6,8,9]. Although secreted signals from the
AVC and OFT myocardium have been shown to induce
endocardial cell EMT [1-4], it has also been demon-
strated that an autocrine TGFβ3 signal is required for
endocardial cell transformation into invasive mesen-
chyme [9,10]. This autocrine signal likely provides amp-
lification or propagation of TGFβ3 signaling within the
endocardium, perhaps activated by the myocardium.
Muscleblind-like 1 (MBNL1) is a known regulator of
pre-mRNA alternative splicing in the developing heart,
driving fetal-to-adult transitions in alternative splicing
[11,12]. MBNL1 has also recently been shown to regu-
late the stability of some mRNA targets [13]. We previ-
ously reported that MBNL1 is differentially expressed in
the embryonic heart during endocardial cushion devel-
opment [14]. Within the endocardial cushions, MBNL1
is highly expressed in the endocardium, but is low or ab-
sent from the underlying myocardium and invaded mes-
enchymal cells. In contrast, outside of the cushion
regions MBNL1 is found in the myocardium but not the
endocardium. Knockdown of MBNL1 in Hamburger and
Hamilton (H&H) stage 14 embryonic chicken AVC
explants with either of two independent siRNAs
enhanced invasion, whereas a control non-targeting
siRNA and an siRNA directed against an unrelated spli-
cing factor had no effect [14]. We demonstrated that this
enhancement of invasion in response to MBNL1 knock-
down is TGFβ3-dependent, but the basis for this de-
pendence had not yet been determined.
In this study, we investigate the relationship between
MBNL1 and TGFβ3 in the AVC and OFT cushions. We
provide evidence that knockdown of MBNL1 leads to
precocious and elevated endocardial-derived TGFβ3
levels in AVC explants, and that early exposure to excess
TGFβ3 leads to precocious and elevated levels of mesen-
chymal cell invasion. Likewise, TGFβ is necessary and
sufficient to stimulate excess invasion in response to
MBNL1 depletion in OFT explants. Taken together,
these data support a model in which MBNL1 acts as a
negative regulator of endocardial cushion EMT by
restricting the timing and amount of autocrine TGFβ3
production in the AVC and OFT endocardium.
Results
Enhancement of cell invasion in the AVC by MBNL1
knockdown is dependent on TGFβ3
TGFβ3 is required for AVC mesenchyme invasion
[6,7,9,10]. This requirement is not abrogated by loss ofMBNL1. We previously demonstrated that the enhance-
ment of cell invasion induced by knockdown of MBNL1
in stage 14 AVC explants can be blocked by inhibitory
antibodies against TGFβs, in particular TGFβ3 [14]. In
those experiments the TGFβ-neutralizing antibodies
were added at six hours. At this time point, blocking
TGFβ effectively abolishes EMT in control as well as
siRNA-treated explants. It is therefore unclear whether
MBNL1 acts through TGFβ3, or merely that TGFβ3 sig-
naling is required to initiate the process of invasion,
which is then acted on by MBNL1 at a later step. To ad-
dress this, we added anti-TGFβ neutralizing antibodies
to mock- or MBNL1 siRNA-treated stage 14 AVC
explants eighteen hours after explantation (Figure 1). At
this time, addition of a pan anti-TGFβ antibody that
inhibits TGFβ1, -2, and −3 had no effect on invasion
in control explants, indicating that the requirement for
TGFβ signaling to induce basal levels of invasion has
passed, presumably because sufficient inductive signal
has already been received. This is consistent with a
previous study that showed anti-TGFβ3 antibodies have
progressively less inhibitory effect on invasion in AVC
explants taken from progressively later stages, suggest-
ing that over time an increasing number of cushion
endocardial cells pass the critical requirement for
TGFβ3 [6]. Inhibition of TGFβ did abrogate the in-
crease in invasion induced by anti-MBNL1 siRNA
treatment, however, suggesting that the effects of
MBNL1 knockdown remain dependent on TGFβ sig-
naling. An anti-TGFβ3 inhibitory antibody likewise
reduced invasion to control levels in MBNL1 siRNA-
treated explants. The requirement for TGFβ3 is spe-
cific, as levels of invasion remained elevated in
MBNL1-depleted explants in the presence of an anti-
TGFβ2 inhibitory antibody.
Knockdown of MBNL1 enhances autocrine TGFβ3 in the
AVC endocardium
One possible explanation for the continued dependence
on TGFβ3 for the enhancement of invasion in MBNL1
siRNA-treated explants is that loss of MBNL1 leads to
an increase in TGFβ3. To determine whether TGFβ3
levels are affected by MBNL1 knockdown, secreted
TGFβ protein levels were compared in conditioned
media collected from mock- and MBNL1 siRNA-treated
stage 14 AVC explants by ELISA (Figure 2A). Medium
from siRNA-treated explants contained approximately
twice as much TGFβ3 as medium from control explants.
In contrast, TGFβ2 levels were similar in media from
MBNL1-depleted and control explants.
Within the AVC, TGFβ3 is expressed in the myocar-
dium before, during, and after EMT takes place, but is
not expressed in active form in the endocardium until
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Figure 1 (See legend on next page.)
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Figure 1 Effects of MBNL1 knockdown on cell invasion remain dependent on TGFβ3 after induction of EMT. Stage 14 AVC explants were
transfected with or without MBNL1 siRNA. Anti-TGFβ antibodies or medium alone were added at 18 hours. Representative images of explants
that were mock-transfected plus medium alone (A, A’), MBNL1 siRNA-transfected plus medium alone (B, B’), and MBNL1 siRNA-transfected plus
anti-TGFβ3 antibody (C, C’) were taken in the focal plane of the surface of the gel (A, B, C) and within the gel (A’, B’, C’) to show invaded
mesenchymal cells. Filled arrowheads indicate cells in the focal plane, whereas open arrowheads indicate the same cells out of focus in a
different plane. (D) The number of invaded cells was counted at 38 hrs. The mean number of invaded cells per explant + the standard error of
the mean is shown. Inhibition of TGFβ signaling has little effect on the basal level of cell invasion in mock-transfected explants. Inhibition with a
pan-TGFβ or TGFβ3-specific antibody blocked the enhancement of cell invasion by MBNL1 knockdown, whereas inhibition with a TGFβ2-specific
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Figure 2 Loss of MBNL1 leads to elevated endocardial-produced TGFβ3 levels. Stage 14 AVC explants were transfected with or without
MBNL1 siRNA. At 18 hrs medium was added to intact explants (A) or explants where the myocardium has been removed (B). Supernatants were
collected after 20 hrs of conditioning and assayed by ELISA. The mean levels of secreted TGFβ proteins as percentages of the mock level + the
standard errors of the means are shown. (A) TGFβ3, but not TGFβ2, levels were elevated in the supernatants from MBNL1 siRNA-treated explants.
(B) TGFβ3 levels were elevated in supernatants from MBNL1 siRNA-treated explants in which the myocardium has been removed prior to
conditioning. Immunofluorescence with an anti- TGFβ3 antibody was also performed on mock- (C, C’) or MBNL1 siRNA-transfected (D, D’) stage
14 AVC explants fixed after 38 hrs in culture. Bright field images of the endocardial monolayer in mock-transfected (C) and MBNL1
siRNA-transfected (D) explants correspond to immunofluorescence images for the same fields (C’, D’). (E) Stage 14 AVC explants were transfected
with or without MBNL1 siRNA. After 38 hrs in culture, the myocardium was removed, RNA was harvested, and TGFβ3 levels were evaluated by
real-time RT-PCR. TGFβ3 transcript levels did not change in response to MBNL1 knockdown in AVC endocardial cells. Error bars denote 95%
confidence intervals. An asterisk indicates a significant difference from mock-transfected explants (P≤ 0.05).
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underlying myocardium [14]. To ascertain whether the
increase in TGFβ3 secretion in MBNL1-depleted AVC
explants is endocardially-derived, TGFβ3 levels were
compared in conditioned media collected from mock-
and MBNL1 siRNA-treated stage 14 AVC explants in
which the myocardium was removed (Figure 2B). As
in intact explants, secreted TGFβ3 levels were elevated
in MBNL1-depleted AVC explants lacking the myocar-
dium, indicating loss of MBNL1 has a cell-autonomous
effect on autocrine TGFβ3 production in the endocar-
dium. It may be noted that TGFβ3 levels are elevated
in MBNL1-depleted AVC endocardia to a lesser extent
than in intact MBNL1-depleted AVC explants. This
could indicate a contribution of increased paracrine
TGFβ3 production resulting from a non-cell-autonomous
effect of MBNL1-depleted endocardium on the myocar-
dium. This discrepancy may also result from a reduction
in the endocardial cell population in the absence of the
myocardium. Cardiomyocyte-conditioned medium has
been shown to induce proliferation in AVC endocardial
monolayers [9]. Indeed, the size of the endocardial
monolayer, number of activated endocardial cells, and
amount of invaded mesenchyme were significantly
reduced in both control and siRNA-treated AVC endo-
cardia relative to similarly treated intact AVC explants
(data not shown).
To further confirm that TGFβ3 levels are elevated in
endocardial cells following MBNL1 knockdown, im-
munofluorescence was performed on mock- and siRNA-
transfected stage 14 AVC explants using an anti-TGFβ3
antibody. In control explants, TGFβ3-positive cells were
detected within the endocardial monolayer (Figure 2C).
This is consistent with the detection of active TGFβ3 in
scattered cells within the AVC endocardium during
stages of active EMT [8]. In agreement with our ELISA
data, more TGFβ3-positive cells were detected within
the endocardial monolayers of MBNL1-depeleted
explants than controls (Figure 2D).
In some cases, MBNL1 binding to the 3' untranslated
region of a target mRNA can promote mRNA decay,
and loss of MBNL1 can increase transcript half-life [13].
To determine whether the increase in TGFβ3 levels fol-
lowing MBNL1 knockdown is due to an increase in
TGFβ3 transcripts, RNA was collected from the non-
myocardial cells in mock and MBNL1 siRNA-treated
stage 14 AVC explants and TGFβ3 levels were measured
by real time RT-PCR (Figure 2E). Despite a doubling in
secreted TGFβ3 protein levels, steady state TGFβ3 tran-
script levels exhibited no difference in MBNL1-depleted
explants relative to controls. This indicates that the
effects of MBNL1 on TGFβ3 levels are post-transcrip-
tional, acting at the level of protein production, stability,
or processing.Addition of exogenous TGFβ3 is sufficient to recapitulate
the effects of MBNL1 knockdown in AVC explants
TGFβ3 is necessary and sufficient to induce invasion in
responsive AVC endocardial monolayers in the absence
of the myocardium [9,10]. Supplementation with add-
itional exogenous TGFβ3 protein has been shown to in-
duce increased expression of mesenchymal markers in
intact chick AVC explants [6], but whether or not expos-
ure to extra TGFβ3 would also lead to increased levels
of invasion has not been reported. To determine
whether the presence of extra TGFβ3 protein is suffi-
cient to enhance cell invasion, stage 14 AVC explants
were treated with different doses of recombinant TGFβ3
protein. A trend towards increased cell invasion was
observed, nearly doubling at the highest dose tested
(Figure 3A).
Although the maximum level of invasion observed is
comparable to that seen in MBNL1-depleted explants,
the dose required to produce this effect (200 ng/ml) is
one to two orders of magnitude higher than what has
been shown to induce mesenchymal marker expression
in AVC explants and endocardial monolayers [6,15]. To
evaluate the induction of mesenchymal marker expres-
sion, total RNA was harvested from non-myocardial
cells of stage 14 AVC explants following rTGFβ3 treat-
ment over a similar dose range. Transcript levels for
smooth muscle β-actin (ACTA2) and fibrillin 2 (FBN2),
two EMT markers known to be induced by TGFβ3
[6,15], were assessed by real-time RT-PCR (Figure 3B).
Both ACTA2 and FBN2 transcripts were induced at all
doses tested. This indicates that higher doses of TGFβ3
are necessary to induce invasion than to activate mesen-
chymal gene expression, and that the expression of mes-
enchymal genes is not sufficient to drive invasion.
Consistent with this, Nakajima and colleagues previously
reported a dose-dependent induction of smooth muscle
β-actin protein-positive cells by 2 to 20 ng/ml rTGFβ3
in AVC endocardial monolayers without acquisition of
an invasive phenotype [15].
Loss of MBNL1 induces precocious TGFβ3, and early
exposure to excess TGFβ3 induces precocious invasion
Since TGFβ3 is transiently expressed in the AVC endo-
cardium [6,9], the increase in TGFβ3 levels following
MBNL1 knockdown could be explained in part by a
change in the timing, and not just the levels, of TGFβ3
production. For example, in the absence of MBNL1
endocardial cells may begin secreting TGFβ3 prema-
turely, allowing more to accumulate. Alternatively, loss
of MBNL1 may allow TGFβ3 production in the endocar-
dium to continue longer than normal. To determine
when TGFβ3 levels become elevated in MBNL1-
depleted explants, we performed a time course experi-
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Figure 3 Addition of exogenous TGFβ3 recapitulates the effects
of MBNL1 knockdown. Stage 14 AVC explants were treated with
M199 supplemented with 0 to 200 ng/ml recombinant TGFβ3 at 6
hours. (A) The number of invaded cells was counted at 38 hrs. The
mean number of invaded cells per explant + the standard error of
the mean is shown. Addition of rTGFβ3 induced an increase in cell
invasion, comparable at the highest dose tested to that seen
following MBNL1 siRNA treatment. (B) The myocardium was
removed and total RNA was harvested at 38 hrs. Expression of the
mesenchymal markers ACTA2 and FBN2 were measured by real-time
RT-PCR. Error bars denote 95% confidence intervals. Although the
extent of ACTA2 and FBN2 up-regulation was somewhat variable,
both markers were elevated in each of the pooled samples for all
three doses (individual data not shown). An asterisk indicates a
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Figure 4 Knockdown of MBNL1 induces precocious TGFβ3
secretion. Stage 14 AVC explants were transfected with or without
MBNL1 siRNA. After a boost at 6 hrs, medium was added to the
explants. After 12 hrs, the conditioned medium was removed and
fresh medium was added. This was repeated twice more, and all
supernatants were assayed by ELISA. The mean levels of secreted
TGFβ3 are shown as a percentage of the baseline level in the
medium+ the standard errors of the means. TGFβ3 levels in
supernatants conditioned by mock-treated explants did not rise
above the baseline level found in M199+ alone until 24–36 hrs after
the boost. Supernatants from MBNL1 siRNA-treated explants,
however, had increased levels of TGFβ3 within the first 12 hrs after
the boost. Levels remained elevated until 36–48 hrs after the boost,
when levels were comparable to supernatants from mock-treated
explants. An asterisk indicates a significant difference from
mock-transfected explants (P≤ 0.05) at the same time point.
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transfected stage 14 AVC explants. The media were
replaced with fresh medium every 12 hours until four
conditioned supernatants were collected for each.Secreted TGFβ3 levels were then compared for each
time point between control and MBNL1-depleted
explants. TGFβ3 levels were not detectable above low
baseline levels in the medium alone in control explants
until the third twelve-hour window. In contrast, in
MBNL1-depleted explants, TGFβ3 levels were above the
baseline at all time points, and were significantly higher
than those of control explants during the first 36 hours.
This suggests that loss of MBNL1 not only leads to ele-
vated levels of TGFβ3 secretion, but also precocious
TGFβ3 secretion. In contrast, during the last 12 hours
TGFβ3 levels went down in MBNL1-depleted superna-
tants and were similar to those in the control superna-
tants. This may suggest that MBNL1 is not required for
the down-regulation of autocrine TGFβ3 production at
later stages of cushion development.
Precocious production of TGFβ3 may in turn be pre-
dicted to promote precocious mesenchyme production.
To determine whether early exposure to excess TGFβ3
will induce precocious invasion, stage 14 AVC explants
were treated with recombinant TGFβ3 protein and fixed
at earlier stages of culture (Figure 5). The mean number
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Figure 5 Early exposure to elevated TGFβ3 levels induces
precocious invasion. Stage 14 AVC explants were treated with
M199 supplemented with 0 or 200 ng/ml recombinant TGFβ3. The
number of invaded cells was counted at 12 or 18 hours. The mean
number of invaded cells per explant + the standard error of the
mean is shown in the top panel; the percentage of the total
number of explants that have significant invasion is shown in the
bottom panel. Addition of rTGFβ3 induced an increase in the
number of invaded cells per explant and the number of explants
with cells undergoing invasion. An asterisk indicates a significant
difference from control explants from the same stage (P≤ 0.05).
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At 12 hours, only one of 12 control explants had signifi-
cant levels of invasion (with four invaded cells), a frac-
tion of the total population (8%) that does not
statistically differ from an expected value of 0% by z test
(P = 0.15). In contrast, over 40% of rTGFβ3-treated
explants had significant numbers of invaded cells
(P < 0.001 compared to a hypothetical 0% value, and
P= 0.01 compared to control levels of 8%), some with
ten or more invaded cells. At 18 hours, about half ofcontrol explants had significant invasion, only a few of
which had more than eight invaded cells. In contrast,
more than 85% of TGFβ3-treated explants had signifi-
cant levels of invasion, and a third had more than 20
invaded cells. These results indicate that premature ex-
posure to TGFβ3 does indeed induce precocious as well
as an increased level of invasion.
MBNL1 expression precedes TGFβ3 in the AVC
If MBNL1 limits invasion by preventing precocious
TGFβ3 expression in the AVC endocardium, then its ex-
pression must precede that of TGFβ3 in AVC endocar-
dial cells. Although TGFβ3 is produced in the
myocardium as early as stage 14, active TGFβ3 protein
is not detectable in the AVC endocardium until stages
17–18, commensurate with EMT [6,8,9]. We previously
reported that MBNL1 transcripts are abundant in AVC
endocardium at stages 18 and 23 [14], but the expres-
sion of MBNL1 prior to the onset of EMT had not been
evaluated. To determine whether MBNL1 is expressed
in the AVC endocardium at earlier stages, in situ
hybridization was performed on sagittal sections from
stage 15 and 16 chick embryos. Similar to what was
observed at later stages [14], MBNL1 transcripts were
strongly detected in endocardial cells within the AVC at
stages 15 and 16, but were low or absent in endocardial
cells within the atrium and ventricle (Figure 6A, 6B).
Strong MBNL1 signal is also detected in blood cells. Ad-
jacent sections processed in parallel and hybridized with
MBNL1 sense probes had no detectable signal (data not
shown). There are far fewer AVC endocardial cells at
stages 15–16 than at later stages. To determine the rela-
tive level of MBNL1 expression at different stages, the
AVC region was excised from stages 14, 15, 16, 18, and
23 hearts, total RNA was harvested, and MBNL1 levels
were quantitated by real-time RT-PCR (Figure 6C).
MBNL1 transcripts were detected in the AVC at stage
14, consistent with positive staining in the heart in stage
14 embryos subjected to whole mount in situ
hybridization [14]. The level of MBNL1 increased at
stage 15, and then remained at a steady level in the AVC
through stage 23. Together, these data indicate that
MBNL1 expression does indeed precede the activation
of autocrine TGFβ3 expression in the AVC endocar-
dium, consistent with our model.
Enhancement of invasion by MBNL1 knockdown is
stage-dependent in AVC explants
To determine whether AVC endocardium from later
stages would respond differently to loss of MBNL1, inva-
sion was compared in AVC explants from stage 14, 15,
and 16 transfected with control or MBNL1 siRNAs
(Figure 7). As was seen previously [14], knockdown of
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Figure 6 MBNL1 is expressed in the AVC endocardium prior to EMT. Sagittal sections of H&H stage 15 (A) and stage 16 (B) chick embryos
were hybridized with MBNL1 antisense probes. The regions indicated by red boxes are shown in higher magnification (A’, B’). Filled arrowheads
indicate positively staining endocardial cells in the atrioventricular canal (AVC). Open arrowheads indicate non-expressing endocardial cells in the
atrium. Positive cells in the atria and ventricles (Vent) are blood cells, which are smaller, morphologically distinct, and luminal to the endocardial
lining of the chambers. (C) MBNL1 transcript levels in the AVC were measured by real-time RT-PCR. Error bars denote 95% confidence intervals. An
asterisk indicates a significant difference from the transcript level at stage 14 (P≤ 0.05). Transcript levels did not differ significantly between stages
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Figure 7 The response to knockdown of MBNL1 is temporally
regulated. AVC explants from stage 14, 15, or 16 were transfected
with or without MBNL1 siRNA and the number of invaded cells was
counted at 38 hrs. The mean number of invaded cells per
explant + the standard error of the mean is shown. Levels of
invasion in stage 14 AVC explants treated with MBNL1 siRNA are
comparable to control stage 15 explants, and levels in stage 15 AVC
explants treated with MBNL1 siRNA are comparable to control stage
16 explants. Knockdown of MBNL1 did not stimulate invasion in
stage 16 explants. An asterisk indicates a significant difference from
control explants from the same stage (P≤ 0.05).
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cell invasion. Knockdown in stage 15 AVC explants
also enhanced invasion, whereas knockdown in stage
16 explants had no significant effect. Strikingly, the
level of invasion induced by loss of MBNL1 in stage 14
explants was reminiscent of levels observed for controls
at stage 15, and likewise knockdown in stage 15
explants resulted in levels similar to stage 16 controls.
These results are consistent with accelerated induction
of invasion. The extent of invasion in MBNL1 siRNA-
treated explants from any stage did not exceed that of
the normal level at stage 16. The lack of response in
stage 16 explants is consistent with the normalization
of TGFβ3 levels in the last window of the time course
in Figure 4, and may suggest that while loss of MBNL1
stimulates precocious production of TGFβ3, once auto-
crine TGFβ3 is expressed MBNL1 no longer regulates
its function.
Loss of MBNL1 enhances TGFβ-dependent invasion in
OFT explants
As in the AVC, endocardial cells within the OFT cush-
ions express high levels of MBNL1 transcript [14]. To
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in the OFT, MBNL1 was knocked down in OFT explants
from stage 14 hearts and the extent of activation and in-
vasion were assessed (Figure 8). The results were strik-
ingly similar to those observed in AVC explants. Either
of the two independent siRNAs against MBNL1 stimu-
lated an increase in the number of invaded cells, but had
no significant effect on activation. A control siRNA had
no effect on activation or invasion.
OFT endocardial cells and explants also express
TGFβ3 coincident with active EMT [4,8,9]. To deter-
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Figure 8 Loss of MBNL1 stimulates endocardial cell invasion in OFT e
MBNL1 siRNA. Representative images of mock- (A, A’) or MBNL1 siRNA-trea
the gel (A, B) to show activated endocardial cells and within the gel (A’, B
in the focal plane, whereas open arrowheads indicate the same cells out o
cells were counted at 38 hrs. The mean number of cells per explant + the s
MBNL1 siRNAs, but not a control siRNA, enhanced invasion in OFT explants
significant difference from mock-transfected explants (P≤ 0.05).are also TGFβ-dependent, a pan anti-TGFβ neutralizing
antibody was used to inhibit TGFβ signaling in mock- or
MBNL1 siRNA-treated stage 14 OFT explants. At six
hours, the anti-TGFβ antibody had no effect on the basal
level of invasion in control explants, but it inhibited the
enhancement of invasion following MBNL1 knockdown
(Figure 9A). To determine whether supplemental TGFβ3
protein is sufficient to induce increased cell invasion in
the OFT as well, stage 14 OFT explants were treated
with recombinant TGFβ3 protein. As in the AVC, the
addition of exogenous rTGFβ3 stimulated invasion
(Figure 9B). Together, these results indicate that TGFβ istrol
A’
’B
xplants. Stage 14 OFT explants were transfected with or without
ted (B, B’) OFT explants were taken in the focal plane of the surface of
’) to show invaded mesenchymal cells. Filled arrowheads indicate cells
f focus in a different plane. (C) The numbers of activated and invaded
tandard error of the mean is shown. Transfection with either of two
. Activation was not significantly affected. An asterisk indicates a
Figure 9 Stimulation of cell invasion in OFT explants by
knockdown of MBNL1 is TGFβ-mediated. (A) Stage 14 OFT
explants were transfected with or without MBNL1 siRNA. An anti-
TGFβ antibody or medium alone as added at 6 hrs and again after a
boost at 18 hrs. The number of invaded cells was counted at 38 hrs.
The mean number of invaded cells per explant + the standard error
of the mean is shown. Inhibition of TGFβ repressed the
enhancement of invasion in MBNL1 siRNA-treated explants to
control levels. An asterisk indicates a significant difference from
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cell invasion in response to loss of MBNL1 protein in
the OFT.
Discussion
Autocrine production of TGFβ3 is required for conver-
sion of AVC endocardial cells to invasive mesenchyme
[9,10]. Furthermore, TGFβ3 is necessary and sufficientA
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mock-transfected explants without antibody treatment (P≤ 0.05). (B)
Stage 14 OFT explants were treated with M199 supplemented with
0 or 200 ng/ml recombinant TGFβ3. The number of invaded cells
was counted at 38 hrs. The mean number of invaded cells per
explant + the standard error of the mean is shown. Addition of
rTGFβ3 induced an increase in cell invasion in stage 14 OFT
explants. An asterisk indicates a significant difference from 0 ng/ml
rTGFβ3 (P≤ 0.05).to induce expression of mesenchymal markers in chick
AVC explants [6]. Here we demonstrate: (i) the ability of
MBNL1 knockdown to stimulate invasion in stage 14
AVC explants is dependent on TGFβ3, (ii) endocardial-
derived TGFβ3 is secreted early and at elevated levels
following MBNL1 knockdown, (iii) early exposure to ex-
cess TGFβ3 induces precocious and elevated levels of
mesenchymal cell invasion, and (iv) MBNL1 expression
precedes that of TGFβ3 in the AVC endocardium. To-
gether, these data support a model in which MBNL1
limits mesenchyme formation by restricting the onset
and level of autocrine TGFβ3 production in the cushion
endocardium. After stage 16, endocardial cells within
the cushions begin to produce both active TGFβ3 pro-
tein and invasive mesenchyme [6,8,9]. Strikingly, knock-
down of MBNL1 had no effect on invasion in stage 16
AVC explants, congruous with the idea that MBNL1
prevents the onset of TGFβ3 expression in the endocar-
dium, but not its efficacy once activated.
The autocrine production of TGFβ3 in the cushion
endocardium requires a signal from the myocardium [4].
Addition of exogenous TGFβ3 has been found to pro-
mote invasion in stage 14 AVC endocardial monolayers,
abrogating the need for additional inductive signals from
the myocardium [9,10]. We found that addition of ex-
ogenous TGFβ3 promoted the production of invasive
mesenchyme in stage 14 AVC explants within 12 hours
of culture. These results suggest that it is the activation
of TGFβ3 expression in the endocardium, not acquisi-
tion of responsiveness to TGFβ3 signaling, that is the
key event that regulates the onset of invasion. Although
our model proposes that MBNL1 prevents premature
activation of TGFβ3 in cushion endocardial cells,
MBNL1 continues to be expressed in the AVC and OFT
endocardium at stages when TGFβ3 expression and cel-
lularization of the cushions are well underway [14]. One
possibility is that a myocardial signal is required not to
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viate its repression by MBNL1. A variety of factors
secreted by the myocardium have been implicated in the
induction of EMT, including TGFβs, bone morpho-
genetic proteins (BMPs), vascular endothelial growth
factor (VEGF), hepatocyte growth factor (HGF), a 130-
kDa protein (ES130) subsequently identified as a ribo-
some binding protein 1 homolog (RRBP1), and extracel-
lular matrix components such as hyaluronan [5]. There
is currently no known connection between any of these
inductive factors and MBNL1, nor has a direct link been
demonstrated between any of these and the autocrine
production of TGFβ3 in the endocardium.
An important area of future investigation is to deter-
mine the mechanism by which MBNL1 prevents (and
knockdown of MBNL1 thereby promotes) TGFβ3 ex-
pression in cushion endocardial cells. We found no
change in the steady state levels of TGFβ3 transcripts
following MBNL1 knockdown in AVC endocardial
cells. We also found no evidence of alternative splicing
of TGFβ3 transcripts (data not shown), indicating regu-
lation of TGFβ3 occurs at the protein level. TGFβ pro-
teins are produced and secreted in latent complexes
that are activated in vivo by proteolytic cleavage [16].
Using antibodies that specifically recognize only active
or active and latent TGFβ isoforms, one study reported
that while active TGFβ3 is detectable in cushion endo-
cardium and mesenchyme beginning at stage 17, some
latent TGFβ3 is found in the AVC and OFT endocar-
dium at stages 14–16 [8]. Latent TGFβ-binding pro-
teins (LTBPs) are thought to be important for storage
and proteolysis-mediated release of TGFβ from the la-
tent complex, perhaps by concentrating TGFβ at the
cell surface [16]. A regulatory role for LTBP-1 in endo-
cardial cushion EMT has been identified in mice [17].
The release of active TGFβ proteins from latent com-
plexes can be mediated by several proteases, including
plasmin and thrombospondin [16]. Annexin II is
expressed in stage 16 endocardial cells, and facilitates
plasmin production that subsequently releases active
TGFβ3 in chick AVC explants [18]. MBNL1 could act
directly on the pre-mRNA alternative splicing or
mRNA stability of one or more of these factors, or act
indirectly on TGFβ3 activation by regulating the ex-
pression or activity of an upstream regulator of this
pathway.
Although a role in TGFβ3 activation is plausible, it is
also possible that loss of MBNL1 leads to an increase in
protein production, secretion, or stability. In our ELISA
experiments we investigated only the amount of TGFβ
proteins secreted into the media, and the antibodies we
used for detection in the ELISA and immunofluores-
cence experiments only recognize the activated TGFβ
isoforms. Ongoing studies to identify the directmolecular targets of MBNL1 in the cushion endocar-
dium will be informative in resolving the mechanism by
which MBNL1 acts on TGFβ3 expression.
Although our studies have focused primarily on the
role of MBNL1 in regulating endocardial cell invasion in
the AVC, our data suggest MBNL1 plays a similar role
in the OFT cushions. Knockdown of MBNL1 in stage 14
OFT explants enhanced invasion, and TGFβ was neces-
sary and sufficient for this effect. Autocrine TGFβ3 is
also produced by OFT endocardium, first as a latent
protein and then in active form [8]. TGFβ3 has been
implicated in inducing EMT during the development of
other organ systems in the chick embryo as well, includ-
ing fusion of the palate [19] and outgrowth of limb bud
mesenchyme [20]. Strikingly, MBNL1 is expressed in the
pharyngeal arches and limb buds in both mouse [21]
and chicken embryos (K.R. Brimacombe and A.N. Ladd,
unpublished data), raising the possibility that regulating
the level and timing of TGFβ signals may be a general
and conserved role of MBNL1 in the developing
embryo.
Conclusions
Autocrine TGFβ3 production is important for the for-
mation of invasive mesenchyme from endocardial cells
in the atrioventricular canal and outflow tract cushions.
MBNL1 is expressed in cushion endocardial cells prior
to activation of autocrine TGFβ3, and knockdown of
MBNL1 leads to early and elevated levels of
endocardially-derived TGFβ3 production and mesenchy-
mal cell invasion. We therefore propose that the role of
MBNL1 in the endocardial cushions is to limit the
amount of invasive mesenchyme by regulating the tim-
ing and level of TGFβ3 signaling.
Methods
Ethics statement
Fertilized chicken eggs were purchased from Case
Western Reserve University Squire Valleevue and Valley
Ridge Farms and the Department of Animal Sciences at
Ohio State University, so no animal husbandry was
required on our part. Only early stage, pre-hatch chicken
embryos were used for these studies, which are not sub-
ject to federal regulation and do not require approval
from the Cleveland Clinic Institutional Animal Care and
Use Committee. All embryos used in this study were
taken from stages prior to the development of a differen-
tiated nervous system, so no special measures to
minimize pain and distress were needed.
Explants, siRNA transfection, and treatments
Fertilized Babcock B-300 (Case Western Reserve Univer-
sity Squire Valleevue and Valley Ridge Farms) or Hy-line
W-36 (Ohio State University) White Leghorn chicken
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desired stages were reached. Embryos were staged
according to Hamburger and Hamilton [22]. Collagen
gels were prepared as previously described [14].
For siRNA experiments, AVC or OFT regions were
excised, transfected, and boosted with anti-MBNL1 or
siGLO control siRNAs as previously described [14].
Knockdown of MBNL1 transcripts with anti-MBNL1
siRNA is typically ~60% relative to mock-treated
explants [14]. For anti-TGFβ antibody experiments,
M199+ alone [1X Medium 199 (Mediatech) supplemen-
ted with 1% each ITS (Invitrogen), pen/strep antibiotic
solution, and chick serum] or 10 μg/ml anti-TGFβ anti-
body diluted in M199+ [anti-TGF-β1, -β2, -β3 pan anti-
body (R&D Systems, catalog no. MAB1835), anti-TGFβ2
antibody (R&D Systems, catalog no. AB-112-NA), or
anti-TGFβ3 antibody (R&D Systems, catalog no. AF-
243-NA)] was added to explants. For exogenous growth
factor experiments, 0, 5, 25, 50, 100, or 200 ng/ml active
human recombinant TGFβ3 (R&D Systems, catalog no.
243-B3) was diluted in serum-free M199.
To measure invasion, AVC explants were fixed with
4% paraformaldehyde for 45 min at room temperature
and invaded cells (i.e., cells wholly within the gel matrix)
were counted using a Leica DMIRB microscope fitted
with Hoffman Modulation Contrast optics. To measure
EMT in OFT explants, both activated cells (i.e., isolated
cells on the surface of the gel) and invaded cells were
counted. When determining the percentage of explants
with significant invasion, a threshold of three invaded
cells was used, consistent with earlier studies
[7,10,23,24]. OFT explants were imaged using QCapture
Pro 6.0 software.
Enzyme-linked immunosorbent assay (ELISA)
M199+ was added to explants and medium was col-
lected after conditioning for 12 or 20 hours as indicated.
Secreted TGFβ levels in the conditioned media were
measured by sandwich ELISA. 96-well plates were
coated with 2 μg/ml of a pan-TGFβ capture antibody
(R&D Systems, catalog no. MAB1835) diluted in phos-
phate buffered saline (PBS), overnight at room
temperature. Plates were washed five times with PBS+
0.05% tween-20 and blocked in PBS + 1% BSA for one
hour at room temperature. After five more washes,
100 μl of sample (conditioned supernatant diluted 1:1 in
PBS + 1% BSA) was added per well. A serial dilution of
rTGFβ3 (R&D Systems, catalog no. 243-B3) or rTGFβ2
(R&D Systems, catalog no. 302-B2) was used to generate
a standard curve. M199+ alone was diluted 1:1 in PBS+
1% BSA to establish the baseline level in unconditioned
medium. Samples were incubated for two hours at room
temperature. Plates were washed five times, and 0.4 μg/ml
biotinylated anti-TGFβ3 (R&D Systems, catalog no.BAF243) or anti-TGFβ2 (R&D Systems, catalog no.
BAF302) detection antibody diluted in PBS+ 1% BSA was
added. Plates were incubated two hours at room
temperature, then washed five times. Streptavidin-HRP
(R&D Systems, catalog no. DY-998) was diluted 1:200 in
PBS+1% BSA, added to wells, and incubated for 20 min
at room temperature in the dark. Plates were washed five
times, and 1-Step Slow TMB-ELISA substrate (Pierce) was
added. Plates were incubated at room temperature until a
strong color reaction was observed in the standards, usu-
ally about 20 min, then the reaction was stopped by
addition of 1 M H2SO4. Absorbances were read at 450 nm
and concentrations were calculated from the standard
curve. Baseline measurements from M199+ alone were
subtracted from conditioned supernatant measurements
prior to comparison between experimental samples, ex-
cept for values shown in Figure 4 where absolute mea-
surements were compared directly to baseline levels in
M199+ alone.
Immunofluorescence
After 38 hrs in culture, AVC explants were fixed in 4%
paraformaldehyde for 45 min at room temperature.
Explants were washed twice with PBS and then incu-
bated in permeabilization/blocking solution (3% BSA
and 0.2% Triton X-100 in PBS) for 30 min at room
temperature. Explants were incubated in 10 μg/mL
monoclonal mouse anti-TGFβ3 (R&D Systems, catalog
no. MAB463) in 3% BSA-PBS overnight at 4°C. The
explants were washed once with PBS and incubated in
FITC-conjugated goat anti-mouse secondary antibody
(Jackson ImmunoResearch Laboratories, catalog no.
515-095-003) diluted 1:200 in 3% BSA-PBS for 2 hrs at
room temperature. Explants were washed twice with
PBS and counterstained (5 μg/mL Hoechst 33342 and
0.4 μg/mL DAPI in PBS) for 30 min at room
temperature (Hoechst/DAPI staining not shown). Fol-
lowing a final wash with PBS, explants were mounted
using VECTASHIELD Hard-Set Mounting Medium
(Vector Laboratories) and imaged on a Leica DMIRB
microscope using QCapture Pro 6.0 software.
Real-time RT-PCR
To evaluate TGFβ3, ACTA2, and FBN2 expression in
explants, the myocardium was removed and total RNA
was harvested from the remaining endocardial mono-
layer and endocardially-derived mesenchyme. To evalu-
ate MBNL1 levels during development, total RNA was
harvested from AVC segments excised from stage 14, 15,
16, 18, and 23 hearts. RNA was extracted using Trizol
Reagent (Invitrogen) and quantified using a NanoDrop
1000 (Thermo Scientific). At least five explants or AVC
segments were pooled per sample, and each pooled sam-
ple was treated as a single biological replicate in real-
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RNA was converted to cDNA using the SuperScript
VILO cDNA Synthesis Kit (Invitrogen) and cDNA was
quantified using the Quant-iT OliGreen ssDNA Assay
Kit (Invitrogen). Real-time PCR reactions were carried
out using TaqMan Gene Expression Assays on the
StepOnePlus platform (Life Technologies), with the fol-
lowing reagents: 1X TaqMan Gene Expression Master
Mix, 0.25X TGFβ3 (Gg03371524_m1), 0.25X ACTA2
(Gg03352404_m1), or 0.25X FBN2 (Gg03323683_m1)
FAM-labeled probe duplexed with 1X GUSB VIC-labeled
probe (Gg03358465_m1; Primer Limited), and 5 ng
cDNA. Each sample was run in triplicate and normalized
to beta glucuronidase (GUSB), which did not vary in re-
sponse to treatments or between developmental stages.
Relative expression values for biological replicates were
standardized using the method described by Willems
et al. prior to statistical analysis [25].
In situ hybridization
Embryos were fixed in 4% paraformaldehyde in PBS at
4°C overnight and dehydrated the next day by sequen-
tially washing with 25, 50, 75, and 100% methanol in
PBSw (PBS with 0.1% Tween-20). To embed, embryos
were incubated in the following sequence of solutions:
isopropanol at room temperature for 15 min, fresh iso-
propanol at 68°C for 15 min, isopropanol/paraplast (1:1)
at 68°C for 30 min, liquid paraplast at 68°C twice for
one hour each and once for 30 min, and solidified at
room temperature. Ten micron thick sagittal sections
mounted on charged slides were de-waxed and rehy-
drated in xylene and a 25, 50, 75, and 100% ethanol
series then rinsed in 2X SSPE (300 mM NaCl, 20 mM
NaH2PO4, 2 mM EDTA, pH 7.4). Slides were re-fixed in
4% paraformaldehyde in PBSw at room temperature for
15 min, rinsed in 2X SSPE, incubated in Proteinase K
(3 μg/ml in PBSw) at 37°C for 30 min, and rinsed in 2X
SSPE. Slides were incubated in 0.2 M HCl in PBSw at
room temp for 15 min and rinsed in 2X SSPE. Slides
were then incubated in a humid chamber with
hybridization buffer [1% boehringer block (Roche), 50%
formamide, 5X SSC (0.75 M NaCl, 0.075 M sodium cit-
rate, pH 7.0), 12% DEPC water, 1 mg/ml Torula RNA
(Roche) filtered, 0.1 mg/ml heparin in 1X SSC, 5 mM
EDTA, 0.1% Tween-20, 0.1% CHAPS] at 65°C for 2 hrs
after which they were incubated with RNA probe in
hybridization buffer diluted 3:1000 at 65°C overnight.
Sense and antisense MBNL1 probes were previously
described [14]. The next day, slides were rinsed in 2X
SSPE before being incubated in hybridization buffer at
room temp for 5 min. Sections were then incubated in
post-hybridization solution [5 ml hybridization buffer,
4.7 ml 2X SSPE, 0.3 ml 10% CHAPS] at room temp for
10 min, and then 0.3% CHAPS in 2X SSPE at roomtemp for 20 min. Slides were soaked in 2X SSPE at room
temp for 20 min, and then rinsed with PBSw at room
temp three times for 10 min each. Sections were incu-
bated in Antibody Buffer (PBS with 10% heat inactivated
goat serum, 1% boehringer block, 0.1% Tween-20) at
room temp for 2 hrs. During this time, Antibody Buffer
was pre-blocked with anti-dig AP fab fragments (Roche)
diluted 1:1000 rocking at 4°C. Slides were then incubated
in the pre-blocked Antibody Buffer at room temp for
1 hr. Sections were rinsed with 0.1% BSA in PBSw at
room temp three times for 10 min each, then in AP1
Buffer (0.1 M NaCl, 0.1 M Tris pH 9.5, 50 mM MgCl2)
at room temperature for 10 min. Slides were stained
with BM Purple (Roche) at 4°C in the dark until desired
strength of staining was reached. Slides were then placed
in Stop Solution (100 mM Tris pH 7.4, 1 mM EDTA) at
4°C in the dark for 15 minutes before being dehydrated
in a 25, 50, 75, and 100% ethanol series and xylene and
finally mounted with Permount (Fisher Scientific). Sec-
tions were imaged on a Leica DM2500 microscope using
QCapture Pro 6.0 software. Brightness, contrast, and
color balance were adjusted using Adobe Photoshop
software to match the appearance of the sections when
viewed through the microscope by eye.
Statistics
Data are reported as the mean plus the standard error of
the mean unless otherwise noted. Real-time RT-PCR
data are reported as the mean flanked by the upper and
lower 95% confidence intervals. Comparisons between
means were performed via one-tailed t-tests assuming
unequal variances. Comparisons between proportions of
explants with significant invasion (Figure 5) were per-
formed via z-test. Differences were considered statisti-
cally significant when P ≤ 0.05.
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